Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Inclusion Criteria:

* The patient has given informed consent.
* The patient is willing and able to abide by the protocol.
* The patient is between age 18 and 70 (between 19 and 70 in Alabama).
* The patient has histologically proven NSCLC with radiologically documented brain metastases.
* Newly diagnosed or stable systemic disease, on or off systemic therapy.
* If receiving systemic therapy for NSCLC, at least two weeks since patient received systemic therapy.
* Able to withhold systemic therapy for duration of WBRT therapy.
* If the patient is of childbearing potential, he/she is using an acceptable/effective method of contraception.
* The patient's Karnofsky Score is greater than or equal to 70%.

Exclusion Criteria:

* Patient has a diagnosis of recurrent brain metastases.
* The patient has an absolute neutrophil count less than or equal to 1.5 X 10 9/L.
* The patient has a screening platelet count less than 100,000/uL.
* The patient has a screening bilirubin greater than 1.6 mg/dL.
* The patient has a screening creatinine greater than 2.25 mg/dL in men and 1.8 mg/dL in women.
* The patient has a screening ALT/AST greater than 2.5 times the upper limit of the laboratory reference range.
* The patient has an unstable medical condition or significant comorbid pathophysiology (e.g. active infection, poorly controlled diabetes, unstable angina, severe heart failure) that would interfere with his/her participation in the study.
* The patient is enrolled, or plans to enroll, in a concurrent treatment protocol with another investigational product.
* The patient has received prior chemotherapy or radiation therapy within two weeks of beginning WBRT on protocol.
* The patient is allergic to gadolinium contrast.
* More than 21 days has or will elapse between the brain MRI documenting the brain metastases and the initiation of WBRT.